FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application for Dasatinib submitted by Prasco Laboratories. The action approves an additional submission under NDA 021986.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

SUPPL AP for DASATINIB (DASATINIB)